Skip to main content

Table 1 Patient characteristics at baseline in the randomized trial

From: The use of patient-reported outcomes to detect adverse events in metastatic melanoma patients receiving immunotherapy: a randomized controlled pilot trial

  Control N = 73 (%) Intervention N = 73 (%) P-values
Random assignment 73
 Ipilimunab 3 (4) 4 (6) 0.956
 Pembrolizumab 36 (49) 38 (52)  
 Nivolumab 13 (18) 11 (15)  
 Ipilimumab+Nivolumab 21 (29) 20 (28)  
Age
 Median (range) 66 (32; 83) 66 (34; 87) 0.619
Sex
 Male 43 (59) 35 (48) 0.184
 Female 30 (41) 38 (52)  
ECOG Performance status   
 0 52 (72) 49 (69) 0.582
 1 19 (26) 19 (27)  
 2 1 (1) 3 (4)  
Disease stage
 Stage III 12 (16) 10 (14) 0.818
 Stage IV 61 (84) 63 (86)  
Line of therapy
 Adjuvant 13 (18) 11 (15) 0.841
 1st line 52 (71) 52 (71)  
 2nd line 6 (8) 6 (8)  
 3rd line 2 (3) 4 (5)  
Lactate dehydrogenase
 Normal 51 (76) 46 (69) 0.334
 Elevated 16 (24) 21 (31)  
BRAF status
 Mutated 31 (42) 32 (44) 0.710
 Wild type 30 (41) 27 (37)  
 Unknown 12 (16) 14 (19)  
Experience with electronic devices
 None 0 (0) 3 (6) 0.232
 A little 16 (38) 15 (32)  
 A lot 26 (62) 29 (62)  
Educational level
 Primary/lower sec. 16 (23) 19 (28) 0.731
 Upper secondary 2 (3) 3 (5)  
 Short cycle tertiary 15 (22) 18 (27)  
 Bachelor 30 (43) 23 (34)  
 Master 6 (9) 4 (6)  
\